Patents by Inventor Anthony G. Gristina

Anthony G. Gristina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5817312
    Abstract: The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.
    Type: Grant
    Filed: October 14, 1997
    Date of Patent: October 6, 1998
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Girish Giridhar
  • Patent number: 5770234
    Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.
    Type: Grant
    Filed: December 13, 1996
    Date of Patent: June 23, 1998
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Girish Giridhar
  • Patent number: 5681565
    Abstract: The direct, concentrated local delivery of antibodies, and pooled human immunoglobulins in particular, to tissue surfaces (e.g., wounds, burns, etc.), and biomaterial implant surfaces significantly decreases the rate of infection at those sites and enhances healing. The immunoglobulins serve to opsonize circulating infectants for phagocytosis and killing, prior to microbial adhesion and biofilm formation, and neutralize bacterial toxins. The treatment methodology results in reduced inflammation, reduced complement and tissue damage, and reduced rejection of biomaterials and transplants.
    Type: Grant
    Filed: January 24, 1996
    Date of Patent: October 28, 1997
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Girish Giridhar
  • Patent number: 5591441
    Abstract: A non-specific host immune cell augmentation composition for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.
    Type: Grant
    Filed: February 16, 1994
    Date of Patent: January 7, 1997
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5585106
    Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable particle to prime macrophages for enhanced oxidative response and bacterial killing. The phagocytosable particles should be administered at the time of exposure to contagion, or one day prior to or up to 6-12 hours after exposure. Administration can be performed by any suitable means which will bring the particles quickly into contact with the blood stream where they will encounter phagocytes and cause priming of the patient's macrophages. The augmentation technique provides for non-specific cellular immunity from a wide range of contagion.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: December 17, 1996
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Girish Giridhar
  • Patent number: 5530102
    Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue at times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, CNS, Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.
    Type: Grant
    Filed: May 15, 1995
    Date of Patent: June 25, 1996
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5505945
    Abstract: Compositions containing a high concentration of the full repertoire of immunoglobulins, including IgA, IgM and IgG, are used to combat infections from microorganisms and viruses at a wound, surgical, or burn site, or normal tissue times of risk of infection. The compositions can contain elevated antibody titers for several specific pathogens including S. aureus, Coagulase Negative Staphylococci Enterococci, S. epidermidis, P. aeruginosa, E. coli, and Enterobacter spp., etc. The compositions are applied directly to a wound or burn site as an ointment, creme, fluid, spray, or the like, prior to viral or bacterial attachment or biofilm formation such that adhesion of the pathogens is inhibited and the pathogens closest to the wound or burn site will be pre-opsonized for phagocytic killing prior to toxin release.
    Type: Grant
    Filed: August 25, 1994
    Date of Patent: April 9, 1996
    Assignee: Medical Sciences Research Institute
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 5292513
    Abstract: A non-specific host defense cell augmentation technique for enhanced microorganism killing utilizes any phagocytosable, biocompatible particle to prime macrophages for enhanced oxidative response and bacterial killing. Patients can have the benefits of primed macrophages in one to four days, and experiments have demonstrated over a 100-fold increase in oxidative potential within this time period. The oxidative response and killing potential is non-immunospecific, meaning not one organism, not a vaccine, and broadly applicable simultaneously to bacteria and viruses as well as tumor cells. The effects have been demonstrated to have a seven day duration indicating non-tissue toxic residual effects and potential for repeated use at monthly intervals.
    Type: Grant
    Filed: May 18, 1992
    Date of Patent: March 8, 1994
    Assignee: Anthony G. Gristina
    Inventors: Anthony G. Gristina, Quentin N. Myrvik
  • Patent number: 4229840
    Abstract: The prosthesis includes two components having biocompatible metal balls at one end thereof. The radial component is secured by an affixation to the distal radius. The metacarpel component is implanted by a pair of affixation stems into the second and third metacarpel bones of the hand. The balls are rotatably captured between a pair of cutout plastic spheroidal blocks clamped together by a biocompatible metal shell, which is spacially compatible within the wrist area.
    Type: Grant
    Filed: August 1, 1978
    Date of Patent: October 28, 1980
    Assignee: Pfizer Inc.
    Inventor: Anthony G. Gristina
  • Patent number: 4179758
    Abstract: Means for affixing the scapular component of a shoulder prosthesis to the bony structure of the shoulder includes a T-shaped stem extending from a flange on the device. The stem has a substantially narrow or thin web having one side longer than the other, which disposes the base at an acute angle relative to the flange, such as approximately 15.degree.. The elongated base and the web are inserted through the bony structure with the flange in contact with outer regions. The base and web are cemented within the bone to securely anchor the prosthesis to the bone between them and the flange.
    Type: Grant
    Filed: July 26, 1977
    Date of Patent: December 25, 1979
    Assignee: Howmedica, Inc.
    Inventor: Anthony G. Gristina
  • Patent number: 4040131
    Abstract: Biocompatible metal balls are secured by affixation stems to the humerus and the scapular region of the shoulder. The balls are rotatably captured between a pair of cutout plastic hemispheres, which are secured to each other to form a spheroid by a metal shell. The prosthesis accordingly provides a wide range of articulation with substantially high stability.
    Type: Grant
    Filed: January 7, 1977
    Date of Patent: August 9, 1977
    Assignee: Howmedica, Inc.
    Inventor: Anthony G. Gristina
  • Patent number: 4003095
    Abstract: Biocompatible metal balls are secured by affixation stems to the humerus and the scapular region of the shoulder. The balls are rotatably captured between a pair of cutout plastic hemispheres, which are secured to each other to form a spheroid by a U-shaped collar. The prosthesis accordingly provides a wide range of articulation with substantially high stability.
    Type: Grant
    Filed: April 29, 1976
    Date of Patent: January 18, 1977
    Assignee: Howmedica, Inc.
    Inventor: Anthony G. Gristina